Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 06 Feb 2023

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Bo Jiang
Junyuan Qi
Mingyuan Sun
Weiwei Zheng
Yongyue Wei
Jianxiang Wang
Fengkui Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1101738

3,032 views
7 citations

Original Research

Published on 02 Feb 2023

Low expression of HIF1AN accompanied by less immune infiltration is associated with poor prognosis in breast cancer

in Pharmacology of Anti-Cancer Drugs

Shasha Tang
Dongyang Liu
Yuan Fang
Liyun Yong
Yi Zhang
Mengying Guan
Xiaoyan Lin
Hui Wang
Fengfeng Cai

Frontiers in Oncology

doi 10.3389/fonc.2023.1080910

2,877 views
4 citations

Editorial

Published on 01 Feb 2023

Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer

in Pharmacology of Anti-Cancer Drugs

Alessandro Passardi
Alessandro Bittoni
Zhigang Bai
Zhongtao Zhang
Cornelis Sier
Yulong He
Endrit Shahini
Antonio Giovanni Solimando

Frontiers in Oncology

doi 10.3389/fonc.2023.1147849

1,386 views
3 citations

Review

Published on 31 Jan 2023

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

in Pharmacology of Anti-Cancer Drugs

Hu Li
Pengbo Hu
Yajun Zou
Lijuan Yuan
Yucheng Xu
Xiaohui Zhang
Xiaoyan Luo
Zhiqiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1071415

8,355 views
17 citations

Clinical Trial

Published on 30 Jan 2023

Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy

in Pharmacology of Anti-Cancer Drugs

Yutaka Fukaya
Toshimi Kimura
Yukihiro Hamada
Kenichi Yoshimura
Hiroaki Hiraga
Yuki Yuza
Atsushi Ogawa
Junichi Hara
Katsuyoshi Koh
Atsushi Kikuta

Frontiers in Oncology

doi 10.3389/fonc.2023.1003633

2,439 views
2 citations

Editorial

Published on 25 Jan 2023

Editorial: Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer

in Pharmacology of Anti-Cancer Drugs

Weilong Zhong
Tao Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1121416

2,380 views
11 citations

Editorial

Published on 25 Jan 2023

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives

in Pharmacology of Anti-Cancer Drugs

Alberto Zambelli
Maurizio D’Incalci

Frontiers in Oncology

doi 10.3389/fonc.2022.1115342

2,059 views
1 citation

Review

Published on 25 Jan 2023

A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021

in Pharmacology of Anti-Cancer Drugs

Rina Sa
Yi Xu
Xinbo Pan
Yu Wang
Zhijian Lin
Xiaomeng Zhang
Bing Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1078254

4,818 views
10 citations

Review

Published on 25 Jan 2023

Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival

in Pharmacology of Anti-Cancer Drugs

Lakhveer Singh
Lakshmi Nair
Dinesh Kumar
Mandeep Kumar Arora
Sakshi Bajaj
Manoj Gadewar
Shashank Shekher Mishra
Santosh Kumar Rath
Amit Kumar Dubey
Gaurav Kaithwas

Frontiers in Oncology

doi 10.3389/fonc.2023.1034205

7,825 views
27 citations

Original Research

Published on 23 Jan 2023

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

in Pharmacology of Anti-Cancer Drugs

Jingtong Zhao
Xupeng Mu
Xuejia Hou
Xiaowen Zhang
Ping Li
Jinlan Jiang

Frontiers in Oncology

doi 10.3389/fonc.2023.1111855

3,336 views
8 citations

Review

Published on 19 Jan 2023

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions

in Pharmacology of Anti-Cancer Drugs

Alessandra Merlini
Valeria Pavese
Giulia Manessi
Martina Rabino
Francesco Tolomeo
Sandra Aliberti
Lorenzo D’Ambrosio
Giovanni Grignani

Frontiers in Oncology

doi 10.3389/fonc.2023.1095219

4,274 views
1 citation

Editorial

Published on 18 Jan 2023

Editorial: Investigating drugs used off-label in various cancers

in Pharmacology of Anti-Cancer Drugs

Wang Liu
Benyi Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1130834

1,741 views

Original Research

Published on 12 Jan 2023

Hybrid peptide NTP-217 triggers ROS-mediated rapid necrosis in liver cancer cells by induction of mitochondrial leakage

in Pharmacology of Anti-Cancer Drugs

Hao Yin
Xingyan Fu
Hanyu Gao
Han Gao
Yannan Ma
Xitong Chen
Xueqi Zhang
Shan-Shan Du
Yun-Kun Qi

Frontiers in Oncology

doi 10.3389/fonc.2022.1028600

3,063 views
12 citations

Case Report

Published on 11 Jan 2023

Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration

in Pharmacology of Anti-Cancer Drugs

Fenna de Vries
Adrianus A. J. Smit
Gertjan Wolbink
Annick de Vries
Floris C. Loeff
Eric J. F. Franssen

Frontiers in Oncology

doi 10.3389/fonc.2022.960116

5,580 views
7 citations

Editorial

Published on 10 Jan 2023

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control

in Pharmacology of Anti-Cancer Drugs

Kyoung-Ho Pyo
S. M. Mazidur Rahman
Diana Boraschi

Frontiers in Oncology

doi 10.3389/fonc.2022.1121120

1,665 views

Review

Published on 09 Jan 2023

Anticancer properties of bromelain: State-of-the-art and recent trends

in Pharmacology of Anti-Cancer Drugs

Raffaele Pezzani
Manuel Jiménez-Garcia
Xavier Capó
Eda Sönmez Gürer
Farukh Sharopov
Tchokouaha Yamthe Lauve Rachel
David Ntieche Woutouoba
Antonio Rescigno
Stefania Peddio
Paolo Zucca

Frontiers in Oncology

doi 10.3389/fonc.2022.1068778

40,604 views
35 citations